LifeVantage Corporation (LFVN)
| Market Cap | 101.43M -32.1% |
| Revenue (ttm) | 195.32M -12.2% |
| Net Income | 5.75M -37.1% |
| EPS | 0.45 -35.7% |
| Shares Out | 12.62M |
| PE Ratio | 17.84 |
| Forward PE | 22.23 |
| Dividend | $0.18 (2.24%) |
| Ex-Dividend Date | Jun 1, 2026 |
| Volume | 263,292 |
| Open | 7.94 |
| Previous Close | 7.67 |
| Day's Range | 7.20 - 8.50 |
| 52-Week Range | 3.90 - 15.00 |
| Beta | 0.55 |
| Analysts | Buy |
| Price Target | 7.00 (-12.94%) |
| Earnings Date | May 6, 2026 |
About LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, ... [Read more]
Financial Performance
In fiscal year 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LFVN stock is "Buy." The 12-month stock price target is $7.0, which is a decrease of -12.94% from the latest price.
News
LifeVantage Slides: Investor presentation
LifeVantage has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
LifeVantage downgraded to Hold from Buy at Lake Street
Lake Street downgraded LifeVantage (LFVN) to Hold from Buy with a $5 price target Q3 results came in below expectations and while management maintained its prior FY26 guidance framework, it…
LifeVantage reports Q3 EPS 11c, consensus 16c
Reports Q3 revenue $43.72M, consensus $47.77M. “Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 System were only partially offset by the addition of…
LifeVantage backs FY26 EPS view 60c-80c, consensus 67c
Backs FY26 revenue view $185M-$200M, consensus $192.75M. Backs FY26 adjusted EBITDA view $15M-$19M. The company said, “The Company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnin...
LifeVantage Earnings Call Transcript: Q3 2026
Q3 revenue fell 25.2% year-over-year due to lower MindBody GLP-1 sales, with adjusted EBITDA and net income also declining. Americas saw a notable drop in consultant count, but the company remains debt-free, increased its dividend, and expects full-year results near the low end of guidance.
LifeVantage Quarterly report: Q3 2026
LifeVantage has published its Q3 2026 quarterly earnings report on May 6, 2026.
LifeVantage Earnings release: Q3 2026
LifeVantage released its Q3 2026 earnings on May 6, 2026, summarizing the period's financial results.
LifeVantage Declares Quarterly Dividend
SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellula...
LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026
SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellul...
LifeVantage to Announce Third Quarter Fiscal Year 2026 Results on May 6, 2026
SALT LAKE CITY, April 22, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellul...
LifeVantage receives U.S. patent for Healthy Glow Essentials Stack
LifeVantage (LFVN) Corporation announced it has been granted a United States Patent No. 12,589,067 B2, issued March 31, 2026, for nutritional supplement composition and methods for activating cellular...
LifeVantage Receives U.S. Patent for Healthy Glow Essentials Stack
SALT LAKE CITY, April 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cel...
LifeVantage Inspires with ‘Breakthrough' Announcements at 2026 Momentum Academy in Las Vegas
SALT LAKE CITY, April 20, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cel...
LifeVantage appoints Terrence Moorehead as CEO effective August 5
LifeVantage (LFVN) appointed Terrence Moorehead as the company’s new President and CEO and as a member of the Board, effective August 5. Moorehead is expected to commence employment with LifeVantage…
LifeVantage Appointing Terrence Moorehead as Chief Executive Officer
SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate opt...
LifeVantage Transcript: Water Tower Research Insights Conference
The session highlighted a transformation from retail to direct sales, a rigorous five-pillar approach to product development, and a strong focus on nutrigenomics. With robust financials, international expansion, and an 18-month innovation cadence, significant growth is anticipated.
LifeVantage to Participate in Water Tower Research Insights Conference on Wednesday, April 15, 2026
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cell...
LifeVantage Announces Expansion of its European Footprint with Market Opening in Portugal
SALT LAKE CITY, April 02, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cel...
LifeVantage Transcript: Sidoti March Small-Cap Virtual Conference
The company highlighted strong financials, robust product innovation, and successful integration of a recent acquisition. Growth is expected from international expansion, new product launches, and digital investments, while a CEO succession plan is in progress.
LifeVantage to Participate in the Sidoti Small Cap Conference
SALT LAKE CITY, March 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cell...
LifeVantage files $75M mixed securities shelf
16:31 EDT LifeVantage (LFVN) files $75M mixed securities shelf
LifeVantage Registration statement: Registration Filing
LifeVantage filed a registration statement on March 10, 2026, providing details about a securities offering with the SEC.
LifeVantage Slides: Investor presentation
LifeVantage has posted slides in relation to its latest quarterly earnings report, which was published on March 5, 2026.
LifeVantage price target lowered to $5 from $12 at Lake Street
Lake Street lowered the firm’s price target on LifeVantage (LFVN) to $5 from $12 and keeps a Buy rating on the shares after the company’s second quarter results and updated…
LifeVantage CEO Steve Fife to retire
LifeVantage (LFVN) announced that after nine years at LifeVantage, Steve Fife, president, CEO and a member of the board of directors, has decided to retire in April. Fife will continue…